Country: Awstralja
Lingwa: Ingliż
Sors: APVMA (Australian Pesticides and Veterinary Medicines Authority)
SODIUM HYALURONATE
DECHRA LTD
sodium hyaluronate(17mg/mL)
PARENTERAL LIQUID/SOLUTION/SUSPENSION
SODIUM HYALURONATE UNGROUPED Active 17.0 mg/ml
1 x 3 mL
VM - Veterinary Medicine
HORSE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACER | POL
MUSCULOSKELETAL SYSTEM
INFLAMMATORY JOINT DISEASE | NON-INFECTIOUS JOINT DISEASE
Poison schedule: 4; Withholding period: Zero (0) days; Host/pest details: HORSE: [INFLAMMATORY JOINT DISEASE]; Poison schedule: 4; Withholding period: WHP:Not to be used in horses intended for human consumption.; Host/pest details: HORSE: [INFLAMMATORY JOINT DISEASE]; An aid to the management of non-infectious inflammatory joint diseases in horses only - for intra-articular administration.NOT TO BE USED in horses intended for human consumption
Registered
2023-07-01
HY-50 (SODIUM HYALURONATE STERILE INJECTION 17MG/ML) 53840/137307 Product Name: APVMA Approval No: Label Name: HY-50 (SODIUM HYALURONATE STERILE INJECTION 17MG/ML) Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Constituent Statements: 17 mg/mL Sodium Hyaluronate Claims: To be used by, or under the supervision of, a registered veterinary surgeon. For intra-articular or intravenous administration, as an aid in the management of non- infectious inflammatory joint diseases in horses only. Net Contents: 1 x 3 mL Directions for Use: Restraints: Contraindications: This product should not be administered to horses with a history of hypersensitivity to sodium hyaluronate. This product should not be administered intra-articularly when joint sepsis and/or fractures are present or suspected. Precautions: In cases of severe acute lameness, radiographic evaluation should be carried out prior to HY-50 treatment to ensure that the joints are free from serious intra-articular fractures. Effects on fertility and reproductive function in breeding mares and stallions have not been evaluated. RLP APPROVED Side Effects: Transient, mild swelling and/or heat were observed in 2.7% of joints treated intra-articularly in an open field trial. These self-limiting local signs resolve spontaneously within 48 hours, and do not negate a successful therapeutic outcome. Dosage and Administration: DISCARD UNUSED PORTION IN THE CONTAINER 24 HOURS AFTER BROACHING. Intravenous use: 3 mL intravenously (for a 450-500 kg horse). Single intra-articular injection: 3 mL intra-articularly into medium and large size joints. Smaller joints such as intertarsal, tarsometatarsal and interphalangeal joints can be treated with a 1.5 mL dose. More than one joint may be treated at the same time. Treatment may be repeated after one or more weeks if necessary, but should not exceed three consecutive weekly intravenous injections, or four consecutive weekly injections in the same joint. Remove product from refrigerato Aqra d-dokument sħiħ